Scientific Abstracts

Late-Breaking Abstracts should report recently generated research on important basic, translational, or clinical discoveries in pulmonary, critical care, or sleep medicine.

"All abstracts will be peer reviewed for scientific rigor and importance in order to determine whether they can be accepted for presentation at the conference."

RESEARCH PREVIOUSLY SUBMITTED FOR OUR NOVEMBER 2024 ABSTRACT DEADLINE WILL NOT BE ACCEPTED.

CASE REPORTS ARE NOT ELIGIBLE AS LATE-BREAKING ABSTRACTS.

Late-Breaking abstracts with no data and/or only a promise of future data will not be accepted. Late-breaking scientific abstract must contain:

1. A descriptive title, list of authors and institutions;
2. An introduction/rationale to the study;
3. The methods used;
4. The results of the study including new data not previously published or presented at a major national or international meeting;
5. Conclusions of the study. It is not satisfactory to state: "The results will be discussed."

Abstracts reporting results of meta-analyses and systematic reviews will also be considered.

It is recommended that the abstract content be organized with the following headings: RATIONALE, METHODS, RESULTS, AND CONCLUSIONS.

ALL LATE BREAKING ABSTRACTS NOT MEETING THESE MINIMUM CRITERIA WILL NOT BE ACCEPTED.

Submission Fee

The Presenting Author will be charged a non-refundable processing fee for each abstract, based on their membership status, as follows:

• Member: $135
• Non Member: $190
• Low Income: $60

**International Low Income fee is for Members and Non-Members residing in countries with a Gross National Product per capita of less than $3000: View list of countries to determine your submission fee.

Language

The abstract must be submitted in English. If accepted, the abstract must be presented in English.

Redundancy

1. Each abstract should have a distinctive hypothesis or include a unique methodology that is clearly differentiated from the other abstracts submitted by a single research group.
2. An abstract that fails to meet these criteria will be considered a duplicate.
3. Duplicate abstracts from a single research group will be rejected.

Prior Publication

Abstracts are not to be submitted for consideration if the work covered is to be published or presented at a major national or international meeting prior to the 2025 ATS International Conference. Abstracts of work presented at local or regional meetings may be submitted for consideration. If the abstract is only presented at a local meeting that abstract should not be posted on a publicly available website (or appear in another journal prior to the ATS Conference, even if it is just the abstract that is being published).

Embargo Policy

It is the policy of the ATS that all scientific research-related content included in an abstract to be presented at the ATS International Conference be withheld until after the abstract has been presented at the conference. This includes all interim and final results, whether or not endpoints were met and any other data that would indicate study results.

Exceptions will be granted on a case-by-case basis if:

• the company in question can demonstrate that it is legally-mandated to issue a news release prior to the conference
  OR
• study results have been submitted to ClinicalTrials.gov.

Data or numbers should not be included in a news release; the scientific content should include only legally required information.

The research-related content of the release should also state that the final results will be presented at the ATS International Conference, if that information has been confirmed.

Any questions about the policy should be directed to Dacia Morris, Director, Communications and Marketing, at dmorris@thoracic.org or 212-315-8620.

Research Funding Source

All abstracts must specify funding source: i.e., pharmaceutical firm name, grant name and source or other specific funding source. Compliance to this rule is a prerequisite for review. Abstracts of research funded by tobacco industry sources (whole or in part) will not be considered. If you have no specific funding source, please indicate "none."

Authors

• The person submitting the abstract will automatically be the Presenting Author. The Presenting Author will be listed first.
• The Presenting Author cannot be modified for any reason after January 29, 2025.
• The submitter (Presenting Author) is responsible for ensuring that all co-authors have agreed to be listed on the abstract and have knowledge of the abstract submission.

Disclosure

The Presenting Author must complete the 2025 Abstract Author Disclosure Questions.

Answers must provide attestations and details about:

• financial support received from commercial entities for the work submitted
• other personal financial interests that could be perceived as a potential conflict of interest (COI) relevant to the work submitted
• professional or other financial relationships with the tobacco, vaping, or cannabis industries specifically
• Examples include any payment received from or investments held in companies that are relevant to the subject matter of the abstract, and any patents or other intellectual property that could be perceived to be affected financially by the outcome of the work submitted.

Individual disclosures are not required from each co-author at this stage, however, the submitting author must note in the application any relevant COI reported by each co-author that might be viewed as significant by the research audience, as well as any existing relationship with the tobacco, vaping, or inhaled cannabis-product industries. If later invited to present in conference symposia accredited for continuing medical education, the abstract author will be required to complete a more detailed online COI disclosure form.

• Abstracts of research supported by tobacco industry sources or cannabis entities that promote non-evidence-based uses of inhaled cannabis products for any purpose will not be considered for acceptance. 
• Abstract authors affiliated with a tobacco industry entity, or a cannabis entity that promotes non-evidence-based uses of inhaled cannabis products, at any time during the twelve months preceding the conference are also ineligible to participate as planners or speakers for ATS 2025 sessions. 
• Involvement with non-tobacco nicotine delivery products does not automatically exclude a person from ATS roles, including acceptance of conference abstracts, unless the entity involved is tobacco industry related.

Abstract Length

The total word count of an abstract may not exceed 400 words. Note: The 400 word count is for the abstract body (title, authors' information, institutions, tables, images and spaces between words will not count towards the 400 word count).

Accuracy

Responsibility for accuracy rests with the Presenting Author.

Abbreviations

When using abbreviations, spell the full name out on first mention and follow with the abbreviation in parentheses. Do not abbreviate compounds in the title of the abstract. Use of unfamiliar abbreviations may be grounds for rejection unless definitions are supplied in the abstract.

Table/Graph/Image

A maximum of 1 image can be included per abstract in JPG format only. When including a table it is recommended to save the table as an image and then upload it in to the abstract body. The image will not count towards the 400 word count. Please note: Table/Image/Graph must be legible for review.

Category

There will be a step-by-step process to complete when choosing a category and review group: 1) choose the classification; 2) choose the discipline; 3) choose the subclassification; 4) choose reviewing Assembly.

• You can log off at any time without submitting your abstract and return to continue your work at another time. As long as you do not formally submit the abstract, it can be edited and revised online as many times as you wish but before the deadline.
• If you wish to withdraw your abstract after the abstract has been submitted, but before the deadline Wednesday, Jan. 29, 2025 (5 p.m. ET), follow these steps:
  • Log in to the submission system
  • Click on the abstract title.
  • Click Review My Work and scroll to the end of page.
  • Click on Delete this Submission button.
  • Abstract submission fee is non-refundable.

To withdraw the abstract after the deadline Wednesday, Jan. 29, 2025: Presenting Author must contact support staff via email at ats@support.ctimeetingtech.com. Provide the abstract ID# and title. No abstracts will be withdrawn after March 3, 2025.

• If a minor edit is needed to a submitted abstract, such as a typo or a missing image, please contact abstracts@thoracic.org prior to the submission deadline. Provide the abstract ID#, title, and exact edit.
• If major edits are required to your submitted abstract or case report before the deadline Wednesday, Jan. 29, 2025 (5 p.m. Eastern Time), follow these steps:
  • Log in to the submission system
  • Click on the abstract title.
  • Click Review My Work and scroll to the end of page.
  • Click on Delete this Submission button.
  • Then re-submit by clicking the +New button.

Please note that you will be required to pay the fee for a new submission and the fee for the previous submission will not be refunded.

• No corrections will be allowed after the deadline:

5 p.m. ET, Wednesday, Jan. 29, 2025
Please proofread and edit your abstract carefully before submission!

• Abstracts that meet acceptable scientific and ethical standards and that contain data not previously published or presented will be considered.
• The International Conference Committee reserves the right to reject abstracts based not only on fulfilling submission criteria, but also on relative merit and the special scheduling requirements of the Conference
• You are allowed to state your presentation preference, however, the International Conference Committee will decide on the presentation format of all accepted abstracts (oral or poster). The decision of the presentation format is final.
• Abstracts can be programmed in the following session formats:
  • Mini Symposium: These half-day sessions (2 hours) are made up of thematically-related abstracts presented as oral presentations.
  • Poster Discussion Session: These half-day sessions (2 hours) are made of thematically-related abstracts which are programmed as poster presentations with a viewing and a discussion period.
  • RAPiD: Rapid Abstract Poster Discussion: These half-day sessions (2 hours) are made of thematically-related abstracts which are programmed as poster presentations with a viewing and a discussion period. The session begins with a viewing period. Then each author will orally present a very brief summary of their research with the use of 1 PowerPoint slide, which must be submitted prior to the conference followed by the discussion of the poster themes. If the author does not submit a summary slide, he/she cannot participate in the summary presentations.
  • Thematic Poster Session: These full-day sessions are made up of thematically-related abstracts which are presented in the poster format. Authors are given a specific time to be by their posters at which time the audience can discuss their work with them on a one to one basis.

All Committee decisions regarding abstract schedule are final.

• The Presenting Author (submitter) of accepted abstracts will be expected to present the study at the International Conference.
• Authors scheduled for a poster presentation will be assigned poster board space for a specified period and will be expected to display illustrative material (graphs, charts, and tabular matter).
• Authors scheduled for oral presentations will have 7 minutes for PowerPoint presentation followed by 5 minutes for discussion.
• If accepted, the Presenting Author is required to pay all fees associated with the Conference, including travel, housing and conference registration.
• Changes cannot be made to the abstract schedule.

ePoster

The presenting author in oral and poster presentations must also upload an ePoster prior to the conference.

• Notification of abstract acceptance or rejection will be sent electronically to the Presenting Author in mid-March 2025 at the email address provided in the online submission.Only the presenting author/submitter receives email notifications. He/she is responsible for sharing the details of their submission with any co-authors.
  Please note: Check both your inbox and junk mail folder for your email notification. Email notifications are sent from ats@support.ctimeetingtech.com
• It is the responsibility of the Presenting Author to ensure that the email address is correct because correspondence relating to the abstract will be sent to this address. If your email address changes after the submission deadline, please contact abstracts@thoracic.org
• If you have not received notification by the end of March 2025, please contact ats@support.ctimeetingtech.com or abstracts@thoracic.org.

All accepted abstracts will be published by the American Thoracic Society in the Online Abstract Issue in May 2025.

Accepted abstracts will be available in ATSConference365 and the ATS Conference App as follows:

• ATSConference365 in April 2025*
• ATS Conference App – May 2025*